Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists

Bibliography

• HENDERSON G, MCKNIGHT AT: The orphan opioidreceptor and its endogenous ligand - nociceptin/orphaninFQ. Trends Pharmacol. ScL (1997) 18:293–300.
   PubMed Web of Science ®Google Scholar
• MOLLEREAU C, PARMENTIER M, MAILLEUX P et al: ORLI, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Lett. (1994) 341:33–38.
   PubMed Web of Science ®Google Scholar
• ••Discovery of the ORL-1 receptor.
   Google Scholar
• MEUNIER J-C: Nociceptin/orphaninFQ and the opioid receptor-like ORLI receptor. Eur. j Pharmacol. (1997) 340:1–15.
   PubMedGoogle Scholar
• WANG JB, JOHNSON PS, IMAI Y et al.: cDNN cloning o f an orphan opiate receptor gene family member and its splice variants. FEBS Lett. (1994) 3 4 8:75–79.
   Google Scholar
• FUKUDA K, KATO S, MORI K et al.: cDNN cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. (1994) 343:42–46.
   PubMed Web of Science ®Google Scholar
• CHEN Y, FAN Y, LIU J et al: Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett. (1994) 347:279–283.
   PubMedGoogle Scholar
• MEUNIER J-C: The potential therapeutic value of nociceptin receptor agonists and antagonists. Exp. Opin. Ther. Patents (2000) 10:371–388.
   Google Scholar
• BARLOCCO D, CIGNARELLA G, GIARDINA GAM, TOMA L: The opioid-receptor-like-1 (ORL-1) as a potential target for new analgesics. Eur. J. Med. Chem. (2000)35:275–282.
   PubMed Web of Science ®Google Scholar
• REINSCHEID RK, NOTHACKER HP, BOURSON A, et al: Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science (1995) 270:792–794.
   PubMed Web of Science ®Google Scholar
• ••Discovery of orphanin FQ (nociceptin), the endogenousligand of the ORL-1 receptor.
   Google Scholar
• MEUNIER J-C, MOLLEREAU C, TOLL L et al.: Isolation and structure of the endogenous agonist of the opioid receptor-like ORLI receptor. Nature (1995) 377:532–535.
   PubMedGoogle Scholar
• ••Discovery of nociceptin (orphanin FQ), the endogenousligand of the ORL-1 receptor.
   Google Scholar
• FAWZI AB, ZHANG H, WEIG B, HAWES B, GRAZIANO MP: Nociceptin activation of the human ORLI receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors. Eur. J. Pharmacol (1997) 336:233–242.
   PubMedGoogle Scholar
• HAWES BE, GRAZIANO MP, LAMBERT DG: Cellular actions of nociceptin: transduction mechanism. Peptides (2000) 21:961–967.
   PubMed Web of Science ®Google Scholar
• CONNOR M, VAUGHAN CW, CHIENG B, CHRISTIE MJ: Nociceptin receptor coupling to a potassium conduc-tance in rat locus coeruleus neurons in vitro. Br. J Pharmacol. (1996) 1 1 9:1614–1618.
   Google Scholar
• SLUGG RM, RONNEKLEIV OK, GRANDY DK, KELLY MJ: Activation of an inwardly rectifying K+ conductance by orphaninFQ/nociceptin in vasopressin-containing neurons. Neuroendocrinology (1999) 69:385–396.
   PubMedGoogle Scholar
• KNOFLACH F, REINSCHEID RK, CIVELLI 0, KEMP JA: Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J NeuroscL (1996) 16:6657–6664.
   PubMedGoogle Scholar
• CONNOR M, YEO A, HENDERSON G: The effect of nociceptin on Ca2+ channel current and intracellular Ca 2+ in the SH-SY5Y human neuroblastoma cell line. Br. J. Pharmacol. (1996) 118:205–207.
   PubMedGoogle Scholar
• NICOL B, LAMBERT DG, ROWBOTHAM DJ, SMART D, MCKNIGHT AT: Nociceptin induced inhibition of K+ evoked glutamate release from rat cerebral cortex. Br. Pharmacol (1996) 119:1081–1083.
   PubMed Web of Science ®Google Scholar
• SINISCALCHI A, RODI B, BEANI I, BIANCHI C: Inhibitory effect of nociceptin on [31-1]-5-HT release from rat cerebral cortex slices. Br. J. Pharmacol. (1999) 128:119–123.
   PubMedGoogle Scholar
• ITOH K, KONYA H, TAKAI E, MASUDA H: Modification of acetylcholine release by nociceptin in conscious rat striatum. Brain Res. (1999) 845:242–245.
   PubMedGoogle Scholar
• MURPHY NP, LY HT, MAIDMENT NT: Intracerebroven-tricular orph anin -FQ/n o cicep tin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience (1996) 75:1–4.
   PubMed Web of Science ®Google Scholar
• GINTZLER AR, ADAPA ID, TOLL L, MEDINA VM, WANG L: Modulation of enkephalin release by nociceptin (o r p h an in FQ). Eur. J. Pharmacol. (1997) 325:29–34.
   PubMedGoogle Scholar
• SCHLICKER E, WERTHVVEIN S, KATHMANN M, BAUER U: Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORLI receptors. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 358:418–422.
   PubMedGoogle Scholar
• BRYANT W, JANIK J, BAUMANN M, CALLAHAN P: Orphanin FQ stimulates prolactin and growth hormone release in male and female rats. Brain Res. (1998) 807:228–233.
   PubMedGoogle Scholar
• FABER ES, CHAMBERS JP, EVANS RH, HENDERSON G: Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro. Br. J. Pharmacol. (1996) 119:189–190.
   PubMedGoogle Scholar
• GIULIANI S, MAGGI CA: Inhibition of tachykinin release from peripheral nerve endings of sensory nerves by nociceptin, a novel opioid peptide. Br. J. Pharmacol. (1996) 118:1567–1569.
   PubMedGoogle Scholar
• VAUGHAN CW, INGRAM SL, CHRISTIE MJ: Actions of the ORL-1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. NeuroscL (1997) 17:996–1003.
   PubMedGoogle Scholar
• NICHOLSON JR, PATERSON SJ, MCKNIGHT AT: Charac-terisation of the response in the rat vas deferens to the ORLI agonist nociceptin. Br. J. Pharmacol. (1996) 119:36P.
   Google Scholar
• LOU LG, ZHANG Z, MA L, PEI G: Nociceptin/orphaninFQ activates mitogen-activated protein kinase in Chinese hamster ovary cells expressing opioid receptor-like receptor. J. Neurochem. (1998) 70:1316–1322.
   PubMedGoogle Scholar
• DARLAND T, HEINRICHER MM, GRANDY DK: Orphan-inFQ/nociceptin: a role in pain and analgesia, but so much more. Trends NeuroscL (1998) 21 :215–221.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on the biological role of orphanin FQ/nociceptin.
   Google Scholar
• MOGIL JS, GRISEL JE, REINSCHEID RK, CIVELLI 0, BELKNAP JK, GRANDY DK: OrphaninFQ is a functional anti-opioid peptide. Neuroscience (1996) 75:333–337.
   PubMed Web of Science ®Google Scholar
• •Evidence that nociceptin reverses opioid-mediated stress-induced antinociception and reverses systemic morphine antinociception in mice.
   Google Scholar
• MOGIL JS, GRISEL JE, ZHANGS G, BELKNAP JK, GRANDY DK: Functional antagonism of8-, K-opioidantinociception by OrphaninFQ. NeuroscL Lett. (1996) 214:131–134.
   PubMed Web of Science ®Google Scholar
• JHAMANDAS KH, SUTAK M, HENDERSON G: Antinociceptive and morphine modulatory actions of spinal orphanin FQ. Can. J Physiol. Pharmacol. (1998) 76:314–324.
   PubMed Web of Science ®Google Scholar
• TIAN JH, XU W, FANGY et al: Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br. J. Pharmacol. (1997) 120:676–680.
   PubMed Web of Science ®Google Scholar
• OKUDA-ASHITAKA E, TACHIBANA S, HOUTANI T et al: Identification and characterization of an endogenous ligand for opioid receptor homologue ROR-C: its involvement in allodynic response to innocuous stimulus. Brain Res. Mol. Brain. Res. (1996) 43:96–104.
   PubMedGoogle Scholar
• ROSSI GC, LEVENTHAL L, BOLAN E, PASTERNAK GW: Pharmacological characterization of orphan-in FQ/n o cicep tin and its fragments. J. Pharmacol Exp. Ther. (1997) 282:858–865.
   PubMed Web of Science ®Google Scholar
• DEVINE DP, REINSCHEID RK, MONSMA FJ, JR., CIVELLI 0, AKIL H: The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. (1996) 727:225–229.
   PubMed Web of Science ®Google Scholar
• DEVINE DP, TAYLOR L, REINSCHEID RK, MONSMA FJ, JR., CIVELLI 0, AKIL H: Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropep-tide orphanin FQ. Neurochem. Res. (1996) 21:1387–1396.
   Google Scholar
• MALIN DH, LAKE JR, MOON WD, et al.: Nocicep tin /orph aninFQ (N/OFQ) induces a quasi-morphine abstinence syndrome in the rat. Psychophar-macology. (2000) 151:344–350.
   Google Scholar
• UEDA H, INOUE M, TAKESHIMA H, IWASAWA Y: Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence. J NeuroscL (2000) 20:7640–7647.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates the involvement of ORL-1 receptor inmorphine tolerance and dependence and that the ORL-1 receptor antagonist J-113397 partially attenuates morphine tolerance and dependence.
   Google Scholar
• CICCOCIOPPO R, ANGELETTI S, PANOCKA I, MASSI M: No cicep tin /orphaninFQ and drugs of abuse. Peptides (2000) 21:1071–1080.
   PubMed Web of Science ®Google Scholar
• SANDIN J, GEORGIEVA J, SCHOTT PA, OGREN SO, TERENIUS L: Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learningin rats. Eur. Neurosci. (1997) 9:194–197.
   PubMedGoogle Scholar
• •Reports the involvement of nociceptin in cognition.
   Google Scholar
• NODA Y, MAMIYA T, MANABE T, NISHI M, TAKESHIMA H, NABESHIMA T: Role of nociceptin systems in learning and memory. Peptides (2000) 21:1063–1069.
   PubMedGoogle Scholar
• MANABE T, NODA Y, MAMIYA T, et al: Facilitation of long-term potentiation and memory in mice lacking nocicep tin receptors. Nature (1998) 394:577–581.
   PubMedGoogle Scholar
• ••Shows the ORL-1 receptor is involved in cognition, andestablishes link between LTP and memory.
   Google Scholar
• POMONIS JD, BILLINGTON CJ, LEVINE AS: OrphaninFQ, agonist of orphan opioid receptor ORLI, stimulates feeding in rats. NeuroReport (1996) 8:369–371.
   PubMed Web of Science ®Google Scholar
• •Reports the hyperphagic effect of nociceptin in rats.
   Google Scholar
• FLORIN S, SUAUDEAU C, MEUNIER JC, COSTENTIN J:Nocicep tin stimulates locomotion and exploratory behaviour in mice. Eur.J. Pharmacol. (1996) 317:9–13.
   PubMedGoogle Scholar
• TAKEDA H, TSUJI M, MATSUMIYA T: Changes in headdipping behaviour in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur. Pharmacol. (1998) 350:21–29.
   PubMed Web of Science ®Google Scholar
• JENCK F, MOREAU J-L, MARTIN JR et al.: OrphaninFQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc. Nati Acad. ScL USA (1997) 94:14854–14858.
   PubMedGoogle Scholar
• •Demonstrates that nociceptin regulates acute anxiety responses.
   Google Scholar
• GRIEBEL G, PERRAULT G, SANDER DJ: OrphaninFQ, a novel n eur op ep tide with anti-stress-like activity. Brain Res. (1999) 836:221–224.
   PubMedGoogle Scholar
• KAPUSTA DR, SEZEN SF, CHANG JK, LIPPTON H, KENIGS VA: Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphaninFQ). Life ScL (1997) 60:PL15-PL21.
   Google Scholar
• •Involvement of nociceptin in the control of water balance.
   Google Scholar
• CHAMPION HC, KADOWITZ PJ: Nociceptin, an endoge-nous ligand for the ORLI receptor, has novel hypoten-sive activity in rat. Life ScL (1997) 6 0:PL241–245.
   Google Scholar
• SALIS MB, EMANUELI C, MILIA AF, GUERRINI R,MADEDDU P: Studies of the cardiovascular effects of nociceptin and related peptides. Peptides (2000) 21:985–993.
   PubMedGoogle Scholar
• CALO G, RIZZI A, BOGONI G, et al: The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur. J. Pharmacol. (1996) 31 1:R3–R5.
   Google Scholar
• DOOLEY CT, HOUGHTEN RA: Orphanin FQ: receptor binding and analog structure activity relationships in rat brain. Life ScL (1996) 59:PL23–29.
   PubMedGoogle Scholar
• REINSCHEID RK, ARDATI A, MONSMA FJ, JR., CIVELLI 0:Structure - activity relationship studies on the novel neuropeptide Orphanin FQ. J. Biol. Chem. (1996) 271:14163–14168.
   PubMedGoogle Scholar
• SHIMOHIGASHI Y, HATANO R, FUJITA T, et al.:Sensitivity of opioid receptor-like receptor ORL-1 for chemical modification of nociceptin, a naturally occurring nociceptive peptide. J Biol. Chem. (1996) 271:23642–23645.
   Google Scholar
• REINSCHEID RK, HIGELIN J, HENNINGSEN RA, MONSMAFJ JR., CIVELLI 0: Structures that delineate Orphanin FQ and Dynorphin A pharmacological selectivity. J Chem. (1998) 2 7 3:1490–1495.
   Google Scholar
• GUERRINI R, CALO G, RIZZI A, et al: Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J. Med. Chem (1997) 40:1789–1793.
   PubMed Web of Science ®Google Scholar
• BUTOUR JL, MOISAND C, MARZAGUIL H, MOLLEREAU C, MEUNIER JC: Recognition and activation of the opioid receptor-like ORLI receptor by nocicep tin, nociceptin analogs and opioids. Eur. J. Pharmacol. (1997) 321:97–103.
   PubMed Web of Science ®Google Scholar
• SALVADORI S, GUERRINI R, CALO G, REGOLI D: Structure-activity studies on nociceptin/orphaninFQ: from full agonist, to partial agonist, to pure antagonist. Farmaco (1999) 54:810–825.
   PubMedGoogle Scholar
• CALO G, GUERRINI R, RIZZI A, SALVADORI S, REGOLI D: Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. (2 0 0 0) 129:1261-1283.
   Google Scholar
• CALO G, GUERRINI R, RIZZI A et al.: Structure-activity study of the nociceptin(1-1 3)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med. Chem. (1998) 41:3360–3366.
   PubMedGoogle Scholar
• CALO G, BIGONI R, RIZZI A, GUERRINI R, SALVADORI S, REGOLI D: Nociceptin/orphaninFQ receptor ligands. Peptides (2000) 21:935–947.
   PubMedGoogle Scholar
• LAPALU S, MOISAND C, MARZAGUIL H, CAMBOIS G, MOLLEREAU C, MEUNIER J-C: Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides. FEBS Lett. (1997) 417:333–336.
   PubMed Web of Science ®Google Scholar
• GUERRINI R, CALO G, RIZZI A et al.: Structure-activityrelationships of nociceptin and related peptides: comparison with dynorphin A. Peptides (2000) 21:923–933.
   PubMedGoogle Scholar
• CALO' G, GUERRINI R, BIGONI R et al.: Characterization of [Nphe1]NC(1–13)N112, a new selective nociceptin receptor antagonist. Br. J. Pharmacol. (2000) 129:1183–1193.
   Google Scholar
• ••Disclosure of a peptide antagonist of the ORL-1 receptorwith in vivo activity.
   Google Scholar
• POLIDORI C, CALO' G, CICCOCIOPPO R, GUERRINI R, REGOLI D, MASSI M: Pharmacological characterization of the nociceptin receptor mediated hyperphagia: identification of a selective antagonist. Psychopharma-cology (2000) 148 :430–437.
   PubMedGoogle Scholar
• PRICE M, GISTRAK MA, ITZHAK Y, HAHN EF, PASTERNAK GW: Receptor binding of 3H-nalox one benzoylhydra-zone: a reversible K and slowly dissociable µ opiate. Mol. Pharmacol. (1989) 35:67–74.
   PubMedGoogle Scholar
• DUNNILL RJ, KAIKZAWA K, MCKNIGHT AT, HENDERSON G: Characterization of the actions of naloxone benzoylhydrazone at 1-opioid, K-opioid and ORLI receptors in isolated tissues from rat and guinea-pig. Br. J. Pharmacol. (1996) 119:275P.
   Google Scholar
• NODA Y, MAMIYA T, NABESHIMA T, NISHI M, HIGASH-IOKA M, TAKESHIMA H: Loss of antinociception induced by nalox one benzoylhydrazone in nociceptin receptor-knockout mice. J. Biol. Chem. (1998) 273:18047-18051.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(4)
   Google Scholar
• OKAWA H, HIRST RA, SMART D, MCKNIGHT AT, LAMBERT DG: Studies on the coupling of recombinant ORL-1 receptors to adenylyl cyclase. Br. J Pharmacol. (1998) I23:218P.
   Google Scholar
• ROVER S, ADAM G, CESURA AM et al: High-affinity,non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor. J. Med. Chem. (2000) 43:1329–1338.
   PubMed Web of Science ®Google Scholar
• YEADON M, KITCHEN I: Comparative binding ofli and 8selective ligands in whole brain and pons/medulla homogenates from rat: affinity profiles of fentanyl derivatives. Neuropharmacology (1988) 27:345–348.
   PubMed Web of Science ®Google Scholar
• MOLLEREAU C, MOISAND C, BUTOUR J-L, PARMENTIER M, MEUNIER J-C: Replacement of G1n28° by His in TIVI6 of the human ORLI receptor increases affinity but reduces intrinsic activity of opioids. FEBS Lett. (1996) 395:17–21.
   PubMedGoogle Scholar
• LAPALU S, MOISAND C, BUTOUR J-L, MOLLEREAU C, MEUNIER J-C: Different domains of the ORLI and 1C-opioid receptors are involved in recognition of nociceptin and dynorphin A. FEBS Lett. (1998) 427:296–300.
   PubMedGoogle Scholar
• HAWKINSON JE, ACOSTA-BURRUEL M, ESPITIA SA: Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur.J. Pharmacol. (2000) 389:107–114.
   PubMedGoogle Scholar
• WICHMANN J, ADAM G, ROVER S, CESURA AM, DAUTZENBERG FM, JENCK F: 8-Acenaphthen-1-y1-1-pheny1-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Bioorg. Med. Chem. Lett. (1999) 9:2343–2348.
   Google Scholar
• ROVER S, WICHMANN J, JENCK F, ADAM G, CESURA AM:ORLI receptor ligands: structure-activity relationships of 8-cycloalky1-1-pheny1-1,3,8-triaza-spiro [4.5]decan-4-ones. Bioorg. Med. Chem. Lett. (2000) 10:831–834.
   Google Scholar
• •Detailed SAR study disclosing very high affinity ORL-1 receptor agonists.
   Google Scholar
• JENCK F, WICHMANN J, DAUTZENBERG FM et al.: A synthetic agonist at the orphanin FQ/nociceptin receptor ORLI: Anxiolytic profile in the rat. Proc. Natl. Acad. Sci. USA (2000) 97:4938–4943.
   PubMed Web of Science ®Google Scholar
• ••Disclosure of Ro 64–6198, a selective ORL-1 receptor agonistwith in vivo anxiolytic activity.
   Google Scholar
• THOMSEN C, HOHLWEG R: (8 -Nap h th alen -1 -ylm e th yl-4-o x o-1 -p heny1-1,3,8-triaza-spir o [4 .5]-dec-3-y1)-acetic acid methyl ester (NNC 63–0532) is a novel potent nociceptin receptor agonist. Br. J Pharmacol. (2000) 131:903–908.
   Google Scholar
• KAWAMOTO H, OZAKI S, ITOH Y et al: Discovery of the first potent and selective small molecule opioid receptor-like (ORLI) antagonist: 1-[(3R,41?)-1-cyclooc tylmethy1-3-hydroxymethy1-4-pip eridy1]-3-ethy1-1,3-dihydro-2H-benzimidazol-2-one (J-113397). J Med. Chem. (1999) 42:5061–5063.
   PubMed Web of Science ®Google Scholar
• ••Disclosure of J-113397, the first non-peptide, selectiveORL-1 antagonist.
   Google Scholar
• OZAKI S, KAWAMOTO H, ITOH Y, MIYAJI M, IWASAWA Y, OHTA H: A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORLI) antagonist: J-113397. Eur.J. Pharmacol (2000) 387:R17–R18.
   Google Scholar
• OZAKI S, KAWAMOTO H, ITOH Y et al: In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORLI receptor antagonist. Eur. j Pharmacol (2000) 402:45–53.
   PubMedGoogle Scholar
• •Extensive pharmacological characterisation of J-113397.
   Google Scholar
• OZAKI S, OKUDA S, MIYAJI M et al.: Pharmacological characterization of J-113397, a potent ORLI receptor antagonist. 31' International Narcotic Research Confer-ence. Seattle, USA (200007.
   Google Scholar
• SHINKAI H, ITO T, IIDA T, KITAO Y, YAMADA H, UCHIDA I: 4-Arninoquinolines: novel nociceptin antagonists with analgesic activity. J. Med. Chem. (2000) 43:4667–4677.
   PubMed Web of Science ®Google Scholar
• •Disclosure of JTC-801, a non-peptide ORL-1 antagonist with in vivo activity.
   Google Scholar